Featured Article
Mammography has long been considered the gold standard breast cancer screening method, but research has shown that conventional 2D mammography, which uses a low-dose X-ray to capture images inside the breast from two angles, fails to detect as much as 20 percent of cancers.
Precision Oncology Today
Magazine
Minimal Disease, Maximum Benefit
As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Immunogenomics is on the Way Up
Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.
Trending on Inside Precision Medicine
Rare Variants Can Strongly Affect Menopause and Cancer Risk
Rare variants can have around five times larger effects on menopause timing than do previously identified common variants.
Wearable Sensor Allows Accurate Eye Tracking to Predict Brain Disorders
A small sensor that can be worn on the skin next to the eye can accurately monitor eye movements that can predict neurological disease risk.
Tomosynthesis More Effective than Mammography for Breast Cancer Screening
Mammography has long been considered the gold standard breast cancer screening method, but research has shown that conventional 2D mammography, which uses a low-dose X-ray to capture images inside the breast from two angles, fails to detect as much as 20 percent of cancers.
